Format

Send to

Choose Destination
See comment in PubMed Commons below
Front Psychiatry. 2012 Jun 28;3:62. doi: 10.3389/fpsyt.2012.00062. eCollection 2012.

Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.

Author information

1
Department of Environmental Health Sciences, School of Public Health, University of Alabama at Birmingham Birmingham, AL, USA.

Abstract

Although offering many benefits for several psychiatric disorders, antipsychotic drugs (APDs) as a class have a major liability in their tendency to promote adiposity, obesity, and metabolic dysregulation in an already metabolically vulnerable population. The past decade has witnessed substantial research aimed at investigating the mechanisms of these adverse effects and mitigating them. On July 11 and 12, 2011, with support from 2 NIH institutes, leading experts convened to discuss current research findings and to consider future research strategies. Five areas where significant advances are being made emerged from the conference: (1) methodological issues in the study of APD effects; (2) unique characteristics and needs of pediatric patients; (3) genetic components underlying susceptibility to APD-induced metabolic effects; (4) APD effects on weight gain and adiposity in relation to their acute effects on glucose regulation and diabetes risk; and (5) the utility of behavioral, dietary, and pharmacological interventions in mitigating APD-induced metabolic side effects. This paper summarizes the major conclusions and important supporting data from the meeting.

KEYWORDS:

adiposity; antipsychotic drugs; behavioral interventions; diabetes; obesity; pediatric populations; pharmacologic interventions; schizophrenia

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Support Center